Hikma Pharmaceuticals Regulatory News (HIK)

15 Jan 2009 15:58



Hikma Pharmaceuticals PLC - 

LONDON, 15 January 2009: Hikma Pharmaceuticals PLC ("the company") (LSE: HIK) (Nasdaq Dubai: HIK) announces that in accordance with the FSA announcement on 9 January 2009 with respect to DTR 3.1.2, the following directors and Darhold Limited, a connected person, have pledged shares in the Company.

Samih Darwazah, the Chairman, has pledged 2,195,450 shares as collateral for loans entered into on 17 December 2007, 24 April 2008 and 22 October 2008.

Mazen Darwazah, an executive director, has pledged 400,000 shares as collateral for a loan entered into on 7 January 2009.

Mr Ali Al-Husry, a non executive director, has pledged 1,000,000 shares as collateral for a loan entered into in June 2008.

Darhold Limited, being a connected person of Samih Darwazah, Ali Al-Husry and Mazen Darwazah for the purposes of the Listing Rules, has pledged 37,800,000 shares as collateral for loans entered into in March 2006, May 2007, January, February and April 2008.

- ENDS -

Enquiries:

Brunswick Group 

Jon Coles/ Justine McIlroy + 44 20 7404 5959

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2007, the Group achieved revenues of $449 million (2006 $317 million) and profit attributable to shareholders was $63 million (2006 $55 million). For news and other information, please visit www.hikma.com.